Boeing Drags as the Dow Endures a Bouncy Day

Merck rises after the EMA accepts the company's PD-1 inhibitor MK-3475 for review.

Jun 30, 2014 at 2:30PM
Daily Fool

The market is off to a bumpy start for the short holiday week, with the Dow Jones Industrial Average (DJINDICES:^DJI)bouncing around the chart all day and sitting just under breakeven as of 2:35 p.m. EDT. Most of the index's 30 member stocks are falling on the day. Merck (NYSE:MRK) is among the Dow's top winners with a 0.8% gain. Meanwhile, Boeing (NYSE:BA) bottomed out on the index with a nearly 1% drop. Let's catch up on what you need to know.

Boeing vies for South Korea's contract

Boeing Kc

Boeing's KC-46 tanker. Source: Boeing Media.

Boeing's is bidding for a South Korean contract worth $1.4 billion to deliver tankers capable of refueling military aircraft in flight. South Korea opened for bidding back in March, reportedly pitting Boeing's KC-46 tanker against the A330 from longtime rival Airbus and the B767-300ER from Israeli Aerospace Industries.The South Korean government expects to decide on a winner later this year, and the deal could be another big win for Boeing's KC-46, 179 of which are being delivered to the U.S. Air Force under a 2011 contract.

It's also a chance for Boeing to jump back into the South Korean military market after abruptly missing out on a nearly $8 billion fighter aircraft deal last year. Seoul spurned Boeing's F-15 Silent Eagle after judging the warplane lacking in necessary stealth capabilities, dealing a big blow to Boeing's hopes for a big contract to revitalize its sluggish military aerospace division. The segment saw its contract backlog slide by more than 1% last quarter, with its operating margin decreasing by 1.1% year over year.

Commercial aerospace still drives Boeing's results -- and that segment has been flying high for the company -- but finding new avenues for growth in the military aerospace arena in the current climate of budget cuts would boost the company's investors, who have watched this stock slide by more than 5% to date in 2014.

Meanwhile, European regulators accepted the Merck's submission for approval of its experimental melanoma drug MK-3475. The PD-1 antibody was accepted for review by the FDA in May, and Merck investors need to keep both eyes locked on this drug's outcome.

MK-3475 is one of the biggest blockbuster candidates in the company's pipeline. Merck has already established agreements to investigate the drug in testing with other leading pharmaceuticals, pushing analysts to peg peak sales at up to $3 billion if it is approved. All odds are on that approval, as MK-3475 has performed well in clinical trials and earned a breakthrough therapy status from the FDA during its clinical run. If all goes as planned, this drug could be a huge breath of life into Merck's lagging sales, which have taken patent cliff-related hits lately in falling by more than 3% year over year in its last quarter.

Don't miss out on the long-term stocks that could revolutionize your financial future
The Dow's home to a number of stocks with a huge advantage for long-term investors: Their great high dividend yields. The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Dan Carroll has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers